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Abstract
Early spontaneous preterm birth is associated with inflammation/infection and shortening of the cervix. We hypothesised
that cervico-vaginal production of trappin2/elafin (peptidase inhibitor 3) and cathelicidin antimicrobial peptide
(cathelicidin), key components of the innate immune system, are altered in women who have a spontaneous preterm
birth. The aim was to determine the relationship between cervico-vaginal fluid (CVF) trappin2/elafin and cathelicidin protein
concentrations with cervical length in woman at risk of spontaneous preterm birth. Trappin2/elafin and cathelicidin were
measured using ELISA in longitudinal CVF samples (taken between 13 to 30 weeks’ gestation) from 74 asymptomatic high
risk women (based on obstetric history) recruited prospectively. Thirty six women developed a short cervix (,25 mm) by 24
weeks’ and 38 women did not. Women who developed a short cervix had 2.71 times higher concentrations of CVF trappin2/
elafin from 14 weeks’ versus those who did not (CI 1.94–3.79, p,0.0005). CVF trappin2/elafin before 24 weeks’ was 1.79
times higher in women who had a spontaneous preterm birth ,37 weeks’ (CI: 1.05–3.05, p = 0.034). Trappin2/elafin (.
200 ng/ml) measured between 14+0–14+6 weeks’ of pregnancy predicted women who subsequently developed a short
cervix (n = 11, ROC area = 1.00, p = 0.008) within 8 weeks. Cathelicidin was not predictive of spontaneous delivery. Vitamin D
status did not correlate with CVF antimicrobial peptide concentrations. Raised CVF trappin2/elafin has potential as an early
pregnancy test for prediction of cervical shortening and spontaneous preterm birth. This justifies validation in a larger
cohort.
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Introduction
Preterm birth is a global healthcare problem associated with
significant neonatal morbidity and mortality and substantial
healthcare costs [1–2]. Spontaneous preterm birth (sPTB)
accounts for approximately three quarters of all premature
deliveries and the need for early identification of at-risk women
is widely recognised, since this would facilitate management and
instigation of appropriate interventions. Current predictors
commonly used in clinical practice to assess risk of sPTB include
cervical length and cervico-vaginal fluid (CVF) fetal fibronectin
(fFN), but their use is limited to gestational ages beyond 18 weeks’
and positive predictive power is suboptimal [3]. Earlier and more
accurate prediction of risk would be advantageous. A test which is
safe, easy to perform and globally acceptable would also have
applicability in low to middle income countries where the
incidence of prematurity is high [4].
sPTB is closely linked with underlying inflammation and
infection, and there has been considerable focus on the potential
of inflammatory cytokines as predictive biomarkers [5]. However,
few have questioned whether host defence peptides (antimicrobial
peptides, AMPs;), key components of the innate immune defence
system, might be alternative biomarkers for the same purpose [6].
Several families of AMPs (e.g. whey acidic proteins, trappin2/
elafin, transferrins and human a and b defensins) have been
identified in the female reproductive tract [7–9]. Trappin2/elafin
(also known as peptidase inhibitor 3, PI3), a member of the whey
acidic protein family, possesses anti-elastase and anti-protease 3
properties and exerts both antimicrobial and immunomodulatory
actions at mucosal surfaces [6,10–12]. The PI3 gene produces a
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spliced protein (117 aa; 12.3 kDa) which is cleaved intracellularly
to a mature protein (9.9 kDA, Trappin 2). This can be secreted
and tethered to the extracellular matrix via an exposed cementoin
domain. Trappin2 can be further processed via extracellular
tryptases to soluble elafin (6 kDA), a smaller molecule which is no
longer tethered to the extracellular matrix [10–11].
Trappin2/elafin proteins are usually expressed constitutively at
low concentrations within epithelial cell layers, but synthesis can
be stimulated by lipopolysaccharide and inflammatory cytokines
and down regulated by oestradiol [6,10–11,13]. PI3 mRNA and
associated trappin2/elafin protein has been reported to be
increased in the amnion of women delivering preterm with
chorioamnionitis compared to those without, but conversely also
found to be reduced in amnion from women with preterm
premature rupture of the membranes (PPROM) [14]. Lower
trappin2/elafin CVF concentrations are also reported in low risk
pregnant women presenting with bacterial vaginosis [15]. Less is
known about cathelicidin antimicrobial peptide (cathelicidin) in
the human reproductive tract, but mRNA and protein have been
detected in vaginal epithelium originating from non-pregnant
women [16].
Our knowledge of the utility of CVF AMPs to predict sPTB is
limited; the presence and gestational profiles of AMPs in CVF and
their relation to other immune modulators such as inflammatory
cytokines and vitamin D is not well described. This is despite
growing evidence that inflammatory mediators modulate expres-
sion of AMPs and the recognition that vitamin D is integral to
pathways regulating cathelicidin synthesis and metabolism
[11,15,17,18]. The relation between vitamin D and AMPs is of
particular interest given reports suggesting a role for vitamin D
insufficiency in poor pregnancy outcome [19,20].
Trappin2/elafin has previously been identified as a potentially
useful clinical biomarker of breast cancer [21], and in graft versus
host disease of the skin following bone marrow transplantation
[22]. It follows that better understanding of the role of trappin2/
elafin and cathelicidin in the pathophysiology of spontaneous
preterm birth may provide new avenues for prediction and
treatment of women at high risk of spontaneous labour and early
delivery.
We hypothesised that trappin2/elafin and cathelicidin concen-
trations in CVF would be altered in women at risk of sPTB. This
study, therefore, has investigated the relationships between CVF
trappin2/elafin and cathelicidin concentrations and cervical
length in a cohort of woman at high risk of sPTB (based on
obstetric history). The association between serum vitamin D
concentration and trappin2/elafin and cathelicidin was also
explored.
Materials and Methods
Ethics statement
Samples for AMP analysis were obtained from a subset of
women recruited to a previously reported prospective observa-
tional study (the Cervical Length and Inflammatory Changes:
CLIC study) [23] designed to assess the relationship between
inflammation and cervical shortening in women at high risk (i.e.
women with a previous history or late miscarriage or sPTB) of
sPTB. This study was approved by the Research Ethics
Committee of St Thomas’ Hospital, London UK (06/Q0704/
66). All patients provided written informed consent and self-
reported information on ethnicity, which was classified for analysis
purposes as ‘white, black or other’.
Study population and design
Women were enrolled from two preterm surveillance clinics at
two teaching hospitals in London between 13 and 24 weeks’
gestation from June 2006 until November 2008. Women with a
history of at least one prior spontaneous preterm birth or late
miscarriage between 16 and 34 weeks’ gestation were eligible to
participate. Exclusion criteria were multiple pregnancy, previous
iatrogenic preterm births and inability to give informed consent.
Thereafter, recruits were assessed until 30 weeks’ gestation with
each providing a CVF sample prior to transvaginal cervical length
assessment every two weeks.
However, if the cervical length shortened to less than 25 mm
before 24 weeks’ gestation, women (allocated to the case group)
were offered treatment (either cervical cerclage or vaginal
progesterone) according to clinical practice. In order to ensure
equal numbers for analysis and to explore the impact of treatments
on trappin2/elafin concentration, women were assigned to either
treatment using computer generated open-label randomization by
the study investigator. Samples and scans were then repeated
weekly thereafter in women found to have a short cervix. The use
of vaginally administered natural progesterone (Cyclogest, 400 mg
once daily; Actavis UK Ltd, Devon, UK) was based on current
clinical practice at the time of the study. Women who did not
develop a short cervix by 24 weeks’ gestation were allocated to the
control group. Routine screening for vaginal organisms such as
bacterial vaginosis, Trichomonas vaginalis and Candida was not
included in the study protocol but if women presented with
symptoms, a high vaginal swab was taken and treatment carried
out according to antimicrobial sensitivities.
Cervical length assessment
Cervical length was assessed in accordance with standardised
guidelines [23]. In brief, a sagittal view of the cervix was obtained
with the long axis view of the echogenic endocervical mucosa
along the length of the canal, allowing identification of both the
internal and external os. The linear distance between the external
and internal os was recorded 3 times (in mm) over a minimum of 3
minutes using optimal magnification and zoom settings, and the
shortest measurement recorded. Transfundal pressure was exerted
for 15 seconds and subsequent demonstration of a funnel was
noted. The total closed length in all women was measured and if a
cerclage was present, the closed length cranial to the cerclage was
also recorded.
Sample preparation and AMP analysis
As reported previously [23], a single Dacron swab was obtained
from the posterior vaginal fornix in order to obtain a high vaginal
sample of CVF at each visit. During speculum examination, the
swab was placed in the posterior vaginal fornix for 10 seconds to
achieve saturation, then transferred into 750 ml of standard
phosphate-buffered saline solution containing protease inhibitors
(Complete, Roche Diagnostics GmbH, Germany) and immedi-
ately transported on ice to the laboratory. The swab was removed,
placed in a clean tube, vortexed for 10 seconds and centrifuged
(2600 g for 10 minutes at 4uC). Resultant fluid was collected and
added to the fluid in the original tube. This was mixed and
centrifuged for a further 10 minutes to remove cell debris. Cell-
free supernatants were divided into aliquots (,110 ml) and stored
at -80uC until analysis. Longitudinal trappin2/elafin CVF
concentration analysis was undertaken on 437 individual samples
from 74 women. Women from the control group were included for
analysis if they had provided at least four longitudinal samples
taken over the second trimester. A minimum of six samples were
analysed for each woman who developed a short cervix (cases).
Trappin2/elafin Predicts Preterm Birth
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Remaining samples from n=64 women were used for cathelicidin
analysis. The samples from cases included pre and post
intervention samples, and the sample obtained at the visit when
the cervix was found to be short prior to randomisation to an
intervention. Samples were thawed at room temperature, briefly
vortexed and analysed by ELISA [Trappin2/elafin, HK318;
cathelicidin (LL-37), HK321 from Hycult, Biotech Cambridge]
according to manufacturer’s instructions. Samples used for
trappin2/elafin measurement were diluted in sample buffer (1:10
for control samples and 1:50 or 1:100 for case samples) to ensure
positioning within the standard curve. CVF samples for cathe-
licidin measurement were undiluted. A pooled control sample
achieved by combining a random set of 10 samples was included
in individual plates to control for inter-plate variation. Final
concentrations were calculated from the standard curves using
logistic regression (Stata, Texas Version 11.2). For trappin2/elafin,
the lower limit of detection of the ELISA was 0.878 ng/ml and
maximal limit of detection was 10 ng/ml.
Serum vitamin D analysis
Vitamin (25-OH)D concentrations were measured in all
available serum samples (n = 67) taken at the first study visit using
a chemiluminescent microparticle immunoassay (CMIA) for the
quantitative determination of 25-hydroxyvitamin D (25-OH
vitamin D) in human serum, according to manufacturer’s
instructions (ARCHITECT, Abbott Laboratories, Barcelona).
For analysis, women were grouped into four categories of vitamin
D status: ,25 ng/ml; 25–49.9 ng/ml; 50–74.9 ng/ml and greater
than 75 ng/ml.
Statistical analysis
The sample size was not pre-determined due to inadequate
published data informing the gestational profiles of CVF trappin2/
elafin or cathelicidin concentrations. Rather, it was determined by
the availability of CVF samples. This study and analysis was
therefore exploratory in nature. Trappin2/elafin and cathelicidin
concentrations were expressed as ng/ml. The study was not
designed or powered to directly compare the two treatment groups
or the relation between biochemical markers and spontaneous
preterm birth, but some exploratory comparisons have been
included.
Analysis was undertaken using Stata (version 11.2, Stata Corp,
College Station, Texas). Distributions of data were first established
by examination of distributional plots for raw and transformed
values. Log transformations were applied to trappin2/elafin,
cathelicidin and cytokine concentrations to achieve approximate
Normality.
Where sample concentrations were below the limit of assay
detection, an interval regression method was used, with the
missing values taken as being at an unknown point on the interval
between zero and the smallest positive concentration observed
[24]. When considering multiple measurements from the same
woman, a random effects regression model was used. In order to
determine the difference in trappin2/elafin and cathelicidin
expression in cases and controls prior to treatment, samples up
to and including the visit at which the cervix shortened, but prior
to treatment over a period of time from 13 to 24 weeks’ were
included. Post treatment samples were taken up to 30 weeks’. The
average difference between cases and controls was determined
using a regression model with correction for effect of gestation (2
weekly categories) and interassay plate variation. Adjustments for
body mass index (BMI), maternal age and ethnicity, and current
smoking status were considered. Results were expressed as ratios of
the concentration, and as weekly rates of change as appropriate,
with 95% confidence intervals. Actual p-values are given (usually
to 2 decimal places), except for very small values, shown as p,
0.001.
Spearman’s rank correlations (rs) were used to show general
association between markers. Graphs show geometric mean
concentrations on a log scale, with standard error bars. Some
descriptive data is provided as medians with quartiles. Test
performance was described for prediction of sPTB and shortening
cervix (prior to cervical shortening) using receiver operating
characteristic (ROC) curves, sensitivity, specificity and predictive
values.
Results
One hundred and twelve women were enrolled into the CLIC
observational study [23]. Thirty eight controls and 36 cases
provided suitable samples for longitudinal analysis of CVF
trappin2/elafin. Cathelicidin was measured in a subgroup
(n= 34 controls and n= 30 cases) in whom there was sufficient
CVF sample available. Table 1 summarises the baseline charac-
teristics of the 74 women studied. The median (quartiles)
gestational age of cervical shortening for cases (n = 36) was
19+1.5 weeks (17+3, 21+2).
Women in the control group had numerically more previous
preterm deliveries between 24 and 34 weeks’ gestation and were
more likely to be white compared to women destined to develop a
short cervix (,25 mm at ,24 weeks’ gestation), who reported
more previous second trimester miscarriage and were more likely
to be black. The incidence of bacterial vaginosis was similar
between groups (controls, 16% and cases 14%). The sPTB ,37
weeks’/late miscarriage rate was 16% for controls (n = 6 of 38
women, with one late miscarriage ,24 weeks) and 53% for cases
(short cervix group, n= 19 of 36 women, 8 of which were ,24
weeks’). The demographics and sPTB rates were similar for the
subgroup that provided samples for cathelicidin measurements.
Trappin2/elafin gestational profile
The CVF trappin2/elafin concentration was higher in women
who subsequently developed a short cervix compared to high-risk
controls with normal cervical length (Figure 1, ratio 2.71, CI 1.94
to 3.79, p,0.0005) and was maintained across the gestational
range studied. Trappin2/elafin CVF concentrations were 3 fold
higher than controls when cervical shortening was first detected
(ratio 3.03 CI 1.92 to 4.81, p,0.0005).
The CVF trappin2/elafin concentration in women with a short
cervix at the time of randomisation (prior to start of treatment)
showed a non-significant trend towards reduction when measured
four weeks later in the cerclage group, (ratio: 0.57 CI 0.32 to 1.02,
p = 0.058). Trappin2/elafin was unaffected following four weeks of
vaginal progesterone therapy (ratio: 1.05 CI 0.68 to 1.61,
p = 0.830). Controls showed little gestation related change over a
similar period. Trappin2/elafin measured before 24 weeks’ was
also higher in women who delivered following sPTB at,37 weeks’
compared to those who delivered at term (ratio 1.79, CI: 1.05 to
3.05, p = 0.034). The influence of maternal ethnicity, BMI, age
and current smoking status were also investigated as potential
determinants of CVF trappin2/elafin concentrations, but no
associations were found. As a result, these factors were not
included in the final regression model.
CVF trappin2/elafin as a predictor of a short cervix by 24
weeks and of sPTB
CVF trappin2/elafin measured between 14+0–14+6 weeks of
pregnancy demonstrated a ROC area of 1.00 (n= 11, p = 0.008)
Trappin2/elafin Predicts Preterm Birth
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for prediction of future cervical shortening in women with a
normal cervical length (Figure 2). The areas under the ROC curve
at 14+0 to 15+6, 16+0 to 17+6 and 18+0 to 19+6 weeks’ were 0.85 (CI
0.67 to 1.00; n= 26), 0.76 (CI 0.59 to 0.92; n= 42) and 0.75 (CI
0.58 to 0.92; n= 41) respectively.
A concentration of .200 ng/ml provided the highest specificity
for prediction of a short cervix by 24 weeks’. Performance of a
single trappin2/elafin test, taken at 14+0 and 14+6 weeks’ and the
wider gestational window of 14+0 to 15+6 weeks, for prediction of a
short cervix within 6 weeks and 8 weeks are shown in Table 2. For
Table 1. Demographics of women in study: high risk controls and cases (women who developed a short cervix before 24 weeks’
gestation) providing cervico-vaginal swabs for serial trappin2/elafin measurements throughout gestation.
Characteristic Sub category Controls (n=38) Cases (n =36)
Maternal age in years median (quartiles) 30.0 (22.4,35) 29.5 (27,34)
BMI in (kg/m2) at booking median (quartiles) 27.7 (23,32) 25.1 (23,28.6)
Risk Factors (N%) previous PTB (24–34 weeks) 20 (53) 11 (31)
previous PPROM 21 (55) 20 (56
previous 2nd trimester loss (16–24 weeks) 20 (53) 29 (81)
Current smoker N (%) 3 (8) 2 (6)
Ethnic group N (%) White 12 (32) 4 (11)
Black 23 (60) 30 (83)
Other 3 (8) 2 (6)
doi:10.1371/journal.pone.0100771.t001
Figure 1. Longitudinal measurements of cervico-vaginal fluid (CVF) trappin2/elafin concentrations in women at high risk of
spontaneous preterm birth who develop a short cervix compared to high-risk controls. The top (square symbol) line represents
measurements in women who subsequently developed a short cervix (n = 36). The lower (circle symbol) line represents women in the high-risk
control group who did not develop a short cervix (n = 38).
doi:10.1371/journal.pone.0100771.g001
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prediction of sPTB ,37 weeks’ gestation, the trappin2/elafin
concentration at 14+0 to 15+6 weeks’ was associated with an area
under the ROC curve of 0.72 (CI 0.52 to 0.93; n = 31).
Gestational cathelicidin profile
Cathelicidin concentrations (without adjustment for treatment
or gestation) were similar in early pregnancy (14–18 weeks’) in
women who developed a short cervix by 24 weeks’ (cases, mean
gestation of cervical shortening 19+2 weeks’) and high-risk controls
(Figure 3). Subsequently, cathelicidin increased until 24 weeks’, in
contrast to controls which did not change. Overall, CVF
cathelicidin rose by 12.7% (CI: 7.9 to 17.7; p= 0.008) per week
in cases and fell by 5.6% (CI: 1.5 to 9.6) in controls (mean
difference 19.41% (CI: 12.4 to 26.9, p,0.001) across the
gestations studied.
In women with a short cervix, there was no significant influence
of treatment (cerclage or vaginal progesterone) [P = 0.667]; the
rate of rise in CVF cathelicidin concentrations across gestation was
similar in women receiving progesterone [11.2% (CI: 2.9 to 20.1)]
to those allocated to cerclage treatment [13.5% (CI: 7.7 to 19.6)].
No association between BMI, age or ethnicity and CVF
cathelicidin concentrations were found.
Prediction of a short cervix by 24 weeks’ and sPTB using
CVF cathelicidin measurements
CVF cathelicidin concentrations were not found to be predictive
of a short cervix before 24 weeks’ or for sPTB at ,37 weeks of
pregnancy (data not shown).
Figure 2. Receiver operating characteristic (ROC) curves demonstrating the ability of trappin2/elafin cervico-vaginal fluid values
.200 pg/ml taken at 14–14+6 weeks’ (red line, n=11) and 14–15+6 (blue line, n=26) to predict cervical shortening within# 8 weeks
in pregnant women at high risk of spontaneous preterm birth.
doi:10.1371/journal.pone.0100771.g002
Table 2. Prediction statistics for trappin2/elafin for values .200 ng/ml identifying high risk women who develop a short cervix
within 6 or 8 weeks following the test.
Test Characteristics 14–14
+6 weeks’ (n = 11) to predict a short cervix at 14–15+6 weeks’ (n = 26) to predict a short cervix at
#6 weeks’ #8 weeks’ #6 weeks’ #8 weeks’
Sensitivity (%) 100 100 80 83
Specificity (%) 80 100 81 83
Odds Ratio (%) ‘ ‘ 17.3 65.0
Positive Predictive Value (%) 86 100 73 91
Negative Predictive Value (%) 100 100 87 87
Test taken as a single measurement between either 14+0 to 14+6 or 14+0 to 15+6 weeks’ in cases who developed a short cervix by 24 weeks’.
doi:10.1371/journal.pone.0100771.t002
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Relation between CVF trappin2/elafin, cathelicidin and
cytokines
There was no correlation between trappin2/elafin and any of
the 11 cytokines measured [IL1B, IL4, IL6, IL7, colony
stimulating factor 3 (granulocyte) (CSF3, previously G-CSF),
colony stimulating factor 2 (CSF2, previously GM-CSF), interfer-
on gamma (IFNG), chemokine (C-C motif) ligand 2 (CCL2,
previously MCP-1), chemokine (C-C motif) ligand 4 (CCL4,
previously referred to as MIP-1b) and tumour necrosis factor
(TNF, previously TNF-alpha)]. A weak relationship with CCL2
was observed (rs = 0.1729, p = 0.0025 after adjustment for multiple
testing, n = 437).
In contrast, associations were found between cathelicidin and
the cytokines measured (Table 3). For example, a doubling of
IL1B concentrations in CVF was associated with an 88% increase
in cathelicidin (P,0.001).
Vitamin (25-OH)D serum status in cases and controls
Serum vitamin (25-OH)D concentrations were measured at
study entry in 35 women with a short cervix and 32 with a normal
cervix (Table 4). Distribution between the four vitamin (OH-25)D
categories was similar for both groups. The vitamin (OH-25)D
concentration was not predictive of cervical shortening (area under
ROC curve 0.52, CI: 0.38–0.67). There was no relationship
between serum vitamin D, CVF trappin2/elafin or cathelicidin.
Discussion
Understanding of the relationships between cervico-vaginal host
defence peptides and spontaneous preterm birth is limited. The
novel demonstration that the CVF trappin2/elafin concentration
is raised prior to cervical shortening in women at high risk of sPTB
is indicative of an altered innate immune status early in pregnancy
in these women. The substantive difference between cases and
controls also suggests that measurement of trappin2/elafin may be
a useful biomarker for identifying women at high risk of cervical
shortening; i.e. those who could benefit from additional surveil-
lance and intervention. In contrast, cathelicidin did not distinguish
between high risk women who were likely to develop a short cervix
and those who were not. The associations between cathelicidin
and the cytokines measured suggest that cathelicidin is reflective of
an inflammatory response following cervical shortening.
The reasons for raised CVF trappin2/elafin were not directly
determined in this study. However, there is a wealth of literature
describing the different roles trappin2/elafin proteins play in the
innate immune response [6,11,25,26–30]. Firstly, trappin2/elafin
are well recognised as inhibitors of neutrophil elastase and
Figure 3. Longitudinal measurements of cervico-vaginal fluid cathelicidin concentrations in women at high risk of spontaneous
preterm birth who develop a short cervix compared to high-risk controls. The square symbol line represents measurements in women who
subsequently developed a short cervix (n = 30). The circle symbol line represents women in the high-risk control group who did not develop a short
cervix (n = 34).
doi:10.1371/journal.pone.0100771.g003
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protease 3 which are produced by activated neutrophils [6]. This is
a protective response initiated by inflammatory mediators [11,25]
with trappin2/elafin proteins providing a ‘brake’ to excessive
neutrophil activity and preventing damage of host tissues through
induction of matrix metalloproteinases, glycoproteins, fibronectin
and cadherins [26–28]. Neutrophils can also cause cleavage and
release of elafin from trappin2. [29]. Secondly, trappin2/elafin can
be induced directly in response to local infection, mediating
disruption of bacterial membranes and inhibition of viral
replication and/or attachment to epithelial cells [6,30]. Thirdly,
trappin2/elafin possesses immunomodulatory properties which
generally promote Th1 cytokine production, neutrophil recruit-
ment and NFkB activation in macrophages and dendritic cell
activation [31]. Under some circumstances trappin2/elafin will
also lead to suppression of cytokines dependent on the stage of the
inflammatory process and disease context [31]. There is also
potential for a genetic influence of trappin2/elafin synthesis as
several PI3 polymorphisms have been identified [32,33], but these
are associated with a reduction in elafin expression.
This complexity of trappin2/elafin regulation provides a
challenge to interpretation of data from the present study. Clearly
pregnant women who develop a short cervix display produce more
trappin2/elafin than high risk controls, and this may indeed reflect
the ability to mount an enhanced host-defence response in
response to unknown stimuli in the cervico-vaginal environment.
Given the association between infection and sPTB, we would
postulate that the underlying cause of raised CVF elafin in women
with cervical shortening is the presence of a local subclinical
bacteria/viral infection. In this scenario, trappin2/elafin would be
induced via activation of pathogen recognition receptors (e.g. Toll-
like receptors or RNA helicases) and downstream production of
inflammatory cytokines, and possibly in response to escalating
neutrophil elastase/protease 3 concentration(s). The observation
that trappin2/elafin is raised throughout gestation indicates the
stimulus persists during pregnancy, but that the innate response
involving trappin2/elafin is not sufficient to inhibit cervical
shortening or sPTB. CVF neutrophil elastase concentrations were
not measured, but the potential recruitment of neutrophils, and
release of neutrophil elastase in this scenario (providing a stimulus
to increased CVF trappin2/elafin) provides a compelling expla-
nation as to the mechanism which initiates cervical tissue damage,
leading to shortening.
This hypothesis requires further investigation, as do alternative
explanations such that women at risk of sPTB in this cohort may i)
have constitutively raised trappin2/elafin basal production due to
genetic predisposition or exposure to other stimuli or different
reproductive tract microbiota profiles.
The lack of strong relationship between trappin2/elafin and
CVF cytokine profiles is intriguing given that cytokines such as
IL1B can, in the absence of pathogens, induce trappin2/elafin
expression in vitro. Cytokines were detectable in CVF from
women in the short cervix and control groups in this cohort, but
only GM-CSF and MCP-1 [23] related to cervical shortening and
these showed no correlation with trappin2/elafin. Possibly, as a
result of the substantially raised trappin2/elafin production, there
may be a paradoxical suppression of cytokine production.
Trappin2/elafin has been measured previously in tissues and
CVF from non-pregnant and pregnant women [14–15,34–35]. In
Table 3. Rank correlations between cathelicidin and 11 cytokines measured in matched cervico-vaginal fluid (CVF) samples
(n = 167) taken between 13 and 24 weeks of gestation from 46 women.
Cytokine Spearman correlations (rs) with CVF cathelicidin concentrations P value
Interleukin 1B 0.6194 ,0.001
Interleukin 4 0.5701 ,0.001
Interleukin 6 0.4217 ,0.001
Interleukin 7 0.5165 ,0.001
Interleukin 8 0.5733 ,0.001
Colony stimulating factor 3 0.4557 ,0.001
Colony stimulating factor 2 0.5814 ,0.001
Interferon gamma 0.4913 ,0.001
Chemokine (C-C motif) ligand 2 0.4240 ,0.001
Chemokine (C-C motif) ligand 4 0.4750 ,0.001
Tumour necrosis factor (TNF) 0.5084 ,0.001
doi:10.1371/journal.pone.0100771.t003
Table 4. Serum vitamin (OH-25) D levels in cases (with a short cervix) and controls (with a normal cervix).
Vitamin (25-OH) D category (ng/ml) Cases (cervix ,25 mm) Controls (cervix .25 mm)
,25 8 (23%) 6 (19%)
25–49.9 21 (60%) 22 (69%)
50–74.9 4 (11%) 3 (9%)
.75 2 (6%) 1 (3%)
Total 35 32
doi:10.1371/journal.pone.0100771.t004
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non-pregnant subjects, high CVF trappin2/elafin concentrations
have been associated with greater resistance to HIV infection [34]
and in pregnant women trappin2/elafin was found to be increased
in amnion from women delivering preterm with chorionamnionitis
[14]. These data concur with the suggestion that raised trappin2/
elafin rises in a response to subclinical infection/inflammation and
processes leading to sPTB. Contrasting reports, have suggested
that a failure to induce an appropriate trappin2/elafin response in
CVF or the amnion results in bacterial vaginosis [15] and
PPROM, respectively [14].
Bastek et al. [35], have assessed CVF elafin concentrations in
parallel with cervical length and fFN measurements, in pregnant
women at 20 weeks’ and 23+6 weeks’ gestation [35]. At these
gestations, trappin2/elafin was not useful as a predictor of sPTB.
This reinforces our observations that elafin has a much better
prediction capacity at 14 weeks’, and that this reflects the process
of cervical shortening rather than cervical length per se.
Comparison of trappin2/elafin between the two studies is not
possible as concentrations were not provided by Bastek et al. [35],
but collection of CVF differed and snap-freezing of swabs in
protease inhibitor prior to processing and analysis could release
intracellular pre-trappin2 protein due to lysis of cellular material
collected on the swab. In contrast, in our study swabs were
removed from the protease inhibitor collection media and samples
centrifuged to provide a cell free sample prior to storage at280uC.
A potential limitation of this study, and others, is the use of a
commercial human trappin2/elafin ELISA assay, as it is reported
to detect the 12.3 kDa (pre-trappin 2) and 9.9 kDa (trappin 2)
proteins but is unsuitable for detection of the 6 kD protein (elafin).
This would suggest that the raised CVF trappin2/elafin measured
in our study reflects an increase in trappin2 specifically. However,
using the same antibody, we carried out a pilot study on CVF
samples which showed, using western blot, not only bands relating
to pre-trappin 2 and trappin 2, but also a band at 6 kDa which
approximates the protein size of elafin (data not shown). Future
studies should attempt to define the trappin2/elafin ratio in the
CVF of women who develop a short cervix, as the proteins can
have differing biological properties and excessive neutrophil
elastase can reduce tethering of trappin2 to cell membranes and
induce proteolytic processing of trappin2 into elafin [29].
Despite sharing similar antimicrobial properties, the CVF
cathelicidin profile did not mimic that of trappin2/elafin. The
rise in cathelicidin around 18–19 weeks’ pregnancy coincided with
the mean gestation at which cervical shortening occurred,
prompting administration of vaginal progesterone or a cervical
suture. As there was no impact of treatment, this increment
appeared to be related to the process of cervical shortening.
Indeed, cathelicidin is reported in the literature [17] to play a role
in wound healing as well as in the innate immune response. The
correlation of cathelicidin with CVF cytokines was surprising as in
vitro cathelicidin is not regulated by cytokines, but implies that the
process of cervical shortening does involve both cytokines and
cathelicidin.
There are reports to suggest that cathelicidin is regulated by
vitamin D in vitro, but neither trappin2/elafin or cathelicidin in
the CVF was associated with the women’s vitamin D status as
assessed by measurement of vitamin (OH-25)D. However, this is
not unexpected as the majority of women were vitamin D deficient
which might obscure any association. It would be of interest to
determine whether CVF cathelicidin was induced in a study of
vitamin D supplementation.
The clinical importance of this study lies in the identification of
CVF elafin/trappin2 as a potentially useful tool to screen women
for risk of cervical shortening at a gestational age as early as 14
weeks. Women with raised CVF trappin2/elafin could be stratified
to receive more intensive surveillance such as regular cervical
length transvaginal ultrasound and, at later gestation, to an fFN
test for risk of premature birth. This strategy would optimise
clinical resource use and avoid unnecessary surveillance of women
unlikely to develop a short cervix on the basis of this new test. Most
interventions currently employed to prevent sPTB rely on prior
identification of women with a short cervix, generally only
identified at later gestations (19–22 weeks’) which gives limited
time for effective intervention. Early pregnancy recognition of
those most likely to develop a short cervix would provide the
opportunity for progesterone administration or elective cerclage at
an earlier gestation than currently practised. Use of trappin2/
elafin as an earlier test of risk of sPTB could similarly identify
women suitable for inclusion in clinical trials assessing prophylactic
interventions to prevent premature labour.
These observations require prospective validation in other
cohorts; we have a study underway to validate trappin2/elafin as a
predictor of cervical shortening and sPTB. In parallel, this will
enable assessment of CVF and cervical epithelial cell trappin2/
elafin concentrations, as well as relationships with neutrophil
activity and the CVF microbiome profile.
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